advertisement
Abstract #15842 Published in IGR 2-3
Effect of latanoprost as adjunctive therapy
DesMarchais B; Candal E; Weitzman M; Shields MBCanadian Journal of Ophthalmology 2000; 35: 214-217
BACKGROUND: Latanoprost may be a useful adjunct in some patients receiving maximum tolerated medical therapy. The authors report their clinical experience with latanoprost when added to one or two other glaucoma medications. METHODS: Review of the charts of 53 patients with open-angle glaucoma whose intraocular pressure (IOP) was uncontrolled with one or two glaucoma medications and who had latanoprost added as a second or third drug. Patients whose IOP decreased by 3 mmHg or more were considered to be responders. RESULTS: The shortest length of follow-up was 2.3 months (median, 5.8 months). Latanoprost was given as a second medication to 35 patients, of whom 22 (63%) responded, with a mean IOP reduction of 6.1 mmHg (standard deviation (SD) 2.73 mmHg) (28.7% (SD 12.10%)). Of the 18 patients to whom latanoprost was given as a third medication, 10 (56%) responded, with a mean IOP reduction of 6.3 mmHg (SD 3.86 mmHg) (24.5% (SD 10.12%)). INTERPRETATION: Latanoprost provides additional IOP reduction in some patients with open-angle glaucoma when added to one or two other glaucoma medications.
Dr. M.B. Shields, Department of Ophthalmology/Visual Science, Yale University School of Medicine, 330 Cedar Street, New Haven, CT 06520-8061, USA
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
